Replies to post #19446 on Marker Therapeutics Inc (MRKR)

[Rkmatters]

I would think if they might be able to present some patient combination case studies, mechanism of action insight and/or safety analysis hopefully in time for ASCO. We should also have final data on Phase I next year too.